Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VS-5584 and defactinib in relapsed malignant mesothelioma
NCT02372227Phase 1Terminated
- Sponsor
- Verastem Oncology
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of VS‑5584 in malignant mesothelioma, sponsored by Verastem Oncology. Primary endpoints: Incidence of dose-limiting toxicities at 6 months and Safety and tolerability of the combination of VS-5584 and VS-6063 at 16 months. Started Jan 2015; status: terminated.
02
Drugs
VS‑5584
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT02372227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372227.